📊 MGRX Key Takeaways
Is MGRX a Good Investment? Thesis Analysis
Mangoceuticals faces severe operational distress with collapsing revenues (-26% YoY), massive operating losses (-$18M on $456K revenue), and negative free cash flow of -$5.9M. The company is burning cash at an unsustainable rate with only $1.5M in cash reserves, indicating imminent solvency concerns without significant operational turnaround or capital infusion.
Mangoceuticals shows extremely weak fundamentals: revenue is small and declining, while operating and net losses are massively larger than sales, indicating the business model is not close to sustainable at its current scale. Although the balance sheet has low liabilities and no meaningful debt, ongoing cash burn relative to its cash position creates substantial execution and financing risk unless revenue growth and cost discipline improve materially.
Why Buy MGRX? Key Strengths
- Decent gross margin of 54.9% suggests product economics are viable at scale
- Minimal debt burden with 0.00x debt-to-equity ratio and $890.6K total liabilities
- Current ratio of 1.74x indicates adequate short-term liquidity position
- Debt-free balance sheet with very low leverage
- Positive gross margin suggests the core product can generate unit-level gross profit
- Current ratio above 1.0 indicates near-term obligations are manageable for now
MGRX Investment Risks to Consider
- Revenue in severe decline (-26% YoY) with extremely low absolute revenue ($456K) indicating minimal market traction
- Catastrophic cash burn of -$5.9M in operating cash flow relative to $1.5M cash reserves suggests runway of ~3 months
- Operating margin of -3954% and net margin of -4526% reflect fundamental business model failure with expenses drastically exceeding any revenue generation
- Negative ROE and ROA both below -128% demonstrate complete destruction of shareholder value
- Minimal insider confidence with only 2 Form 4 filings in 90 days
- Revenue declined 26.0% year over year, pointing to weak growth quality and limited operating traction
- Operating loss of $18.03M on just $456.02K of revenue shows extreme cost imbalance and no operating leverage
- Operating cash outflow of $5.85M versus $1.49M cash implies meaningful liquidity pressure if burn continues
Key Metrics to Watch
- Monthly cash burn rate and cash runway until depletion
- Revenue trend stabilization or further deterioration
- Success of cost reduction initiatives to achieve operating cash flow positive status
- Any capital raises or debt financing announcements indicating survival strategy
- Quarterly revenue growth and gross profit dollars
- Operating cash burn relative to ending cash balance
MGRX Financial Metrics
💡 AI Analyst Insight
MANGOCEUTICALS, INC. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MGRX Profitability Ratios
MGRX vs Default Sector
How MANGOCEUTICALS, INC. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MGRX Overvalued or Undervalued?
Based on fundamental analysis, MANGOCEUTICALS, INC. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MGRX Balance Sheet & Liquidity
MGRX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: MANGOCEUTICALS, INC.'s revenue has declined by 16% over the 5-year period, indicating business contraction. The most recent EPS of $-4.80 indicates the company is currently unprofitable.
MGRX Growth Metrics (YoY)
MGRX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $84.2K | -$2.0M | $-0.69 |
| Q2 2025 | $163.2K | -$2.4M | $-0.57 |
| Q1 2025 | $109.3K | -$2.4M | $-1.29 |
| Q3 2024 | $133.4K | -$1.8M | $-0.99 |
| Q2 2024 | $141.2K | -$2.3M | $-0.09 |
| Q1 2024 | $100.7K | -$2.4M | $-0.10 |
| Q3 2023 | $245.2K | -$19.6K | $-0.10 |
| Q2 2023 | $141.2K | -$19.6K | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MGRX Capital Allocation
MGRX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for MANGOCEUTICALS, INC. (CIK: 0001938046)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MGRX
What is the AI rating for MGRX?
MANGOCEUTICALS, INC. (MGRX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MGRX's key strengths?
Claude: Decent gross margin of 54.9% suggests product economics are viable at scale. Minimal debt burden with 0.00x debt-to-equity ratio and $890.6K total liabilities. ChatGPT: Debt-free balance sheet with very low leverage. Positive gross margin suggests the core product can generate unit-level gross profit.
What are the risks of investing in MGRX?
Claude: Revenue in severe decline (-26% YoY) with extremely low absolute revenue ($456K) indicating minimal market traction. Catastrophic cash burn of -$5.9M in operating cash flow relative to $1.5M cash reserves suggests runway of ~3 months. ChatGPT: Revenue declined 26.0% year over year, pointing to weak growth quality and limited operating traction. Operating loss of $18.03M on just $456.02K of revenue shows extreme cost imbalance and no operating leverage.
What is MGRX's revenue and growth?
MANGOCEUTICALS, INC. reported revenue of $456.0K.
Does MGRX pay dividends?
MANGOCEUTICALS, INC. does not currently pay dividends.
Where can I find MGRX SEC filings?
Official SEC filings for MANGOCEUTICALS, INC. (CIK: 0001938046) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MGRX's EPS?
MANGOCEUTICALS, INC. has a diluted EPS of $-2.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MGRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MANGOCEUTICALS, INC. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MGRX stock overvalued or undervalued?
Valuation metrics for MGRX: ROE of -135.8% (sector avg: 15%), net margin of -4,526.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MGRX stock in 2026?
Our dual AI analysis gives MANGOCEUTICALS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MGRX's free cash flow?
MANGOCEUTICALS, INC.'s operating cash flow is $-5.9M, with capital expenditures of $3.5K. FCF margin is -1,283.7%.
How does MGRX compare to other Default stocks?
Vs Default sector averages: Net margin -4,526.8% (avg: 12%), ROE -135.8% (avg: 15%), current ratio 1.74 (avg: 1.8).